Focus: Salvia BioElectronics is a Netherlands-based medical device company developing implantable neurostimulation systems for chronic migraine and cluster headache. The company is early-stage (Series B, founded 2017) with a focused portfolio centered on its PRIMUS platform.
Profile data last refreshed 45m ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
2 added, 3 removed. Backfill posture.
High-risk, high-upside opportunity for early-career clinical or manufacturing professionals willing to bet on a focused neurotech platform with clear clinical utility but unproven market adoption.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Single core platform addressing two high-burden neurological indications with limited existing implantable options.
Help build intelligence for Salvia BioElectronics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Salvia BioElectronics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo